Sarcomas and Histiocytosis

Research Program

Paediatric Cancer

Where we are

SJD Barcelona Children's Hospital

How to reach us

Related websites

Our group aims to generate a knowledge base on developmental sarcomas and Langerhans cell histiocytosis (LCH) with a view to improving diagnosis, prognosis and treatment.

Since 2014 we have been a consolidated AGAUR research group (Government of Catalonia, references 2014 SGR 1398 and 2017 SGR 1672).

Research lines

Our specific activities are:

  1. The study of the aetiology of sarcomas and LCH and the phenotypic and genotypic characterisation of the different clinical subtypes.
  2. The investigation of the existence of cancer stem cells or progenitor cells.
  3. Improving treatments for patients with sarcomas by studying preclinical pharmacology.
  4. The development of IGF-1R-targeted therapies for sarcoma.
  5. The study of molecular pathways and therapies aimed at histiocytosis.
  6. Paediatric Cancer Epigenetics

Scientific objectives

  1. To develop innovative pharmacological treatments for extracranial paediatric solid tumours such as Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma and LCH.
  2. To describe the cell of origin in Ewing's sarcoma and to develop experimental models to reproduce the tumourigenesis process.

Area/Field of expertise

Development of cell models and patient-derived xenografts (PDX) of paediatric solid tumours (rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, Wilms tumour, germ cell tumours) from biobank samples.

Efficacy tests of anticancer agents used to treat paediatric solid tumours.

Epigenomics and chromatin conformation studies using chip-Seq, CHIP-CHIP, HI-Seq.

Group members

Last Publications

More Publications

Projects

Project name:
El epigenoma malvado de los tumores rabdoides - definir para tratar.
Leader
Alexandra Avgustinova
Funding entities:
Ministerio de Economía Y Competitividad (MINECO)
Code
PID2020-118241RA-I00
Starting - finishing date:
2021 - 2024
Project name:
Influencia del contexto epigenético en la edad como factor pronóstico en Ewing Sarcoma
Leader
Jaume Mora Graupera
Funding entities:
Instituto de Salud Carlos III (ISCIII)
Code
PI20/00179
Starting - finishing date:
2021 - 2023
Project name:
Ayudas para contratos Ramón y Cajal (RYC) 2019. Beneficiario: Alexandra Avgustinova
Leader
Alexandra Avgustinova
Funding entities:
Ministerio de Economía Y Competitividad (MINECO)
Code
RYC2019-027738-I
Starting - finishing date:
2020 - 2025
More projects

Theses

  • Combined therapies for neuroblastoma based on the activation of the calcium sensing receptor
    Author
    Gonçalves Alves, Eliana Carolina
    Institution
    UNIVERSIDAD DE BARCELONA
    15/01/2021
  • Polycomb and KDM6A Roles in the Epigenetic Dynamics of Ewing Sarcoma Tumorigenesis”
    Author
    Figuerola Bou, Elisabet
    Institution
    UNIVERSIDAD DE BARCELONA
    05/12/2019
  • Influence of the epigenetic background in the generation and treatment of Ewing Sarcoma
    Author
    Sanchez Jimenez, Maria
    Institution
    UNIVERSIDAD DE BARCELONA
More Theses

News

See All news